Euro vs US Dollar

Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.

Registrieren

TGTX TG Therapeutics Inc

17,70

0,00 (0,00%)

Vor Marktöffnung

Zuletzt aktualisiert: 10:00:00

Verzögert um 15 Minuten

Biotech Massively Bid Up Before Opening Bell

A North Carolina-based biotech firm is turning heads so far Tuesday morning after it was announced a strategic transaction with TG Therapeutics Inc.

To read the full story on AllPennyStocks.com, click here.

TG Therapeutics (NASDAQ:TGTX)
Historical Stock Chart
Von Apr 2024 bis Mai 2024

Click Here for more TG Therapeutics Charts.

TG Therapeutics (NASDAQ:TGTX)
Historical Stock Chart
Von Mai 2023 bis Mai 2024

Click Here for more TG Therapeutics Charts.

News TG Therapeutics Inc

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Montag 6 Mai 2024 (2 Wochen vor) • Edgar (US Regulatory)

TG Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
Mittwoch 1 Mai 2024 (3 Wochen vor) • GlobeNewswire Inc.

TG Therapeutics to Host Conference Call on First Quarter 2024 Financial Results and Business Update
Dienstag 30 April 2024 (3 Wochen vor) • GlobeNewswire Inc.

TG Therapeutics Announces Additional Data Presentations for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting
Donnerstag 18 April 2024 (1 Monat vor) • GlobeNewswire Inc.

TG Therapeutics Awarded National Contract by the Department of Veterans Affairs for BRIUMVI as the Preferred Anti-CD20 for Relapsing Forms of Multiple Sclerosis
Donnerstag 18 April 2024 (1 Monat vor) • GlobeNewswire Inc.

TG Therapeutics Announces Presentation of Data for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting
Montag 15 April 2024 (1 Monat vor) • GlobeNewswire Inc.

TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting
Freitag 8 März 2024 (2 Monate vor) • GlobeNewswire Inc.

TG Therapeutics Announces Presentation of Data for BRIUMVI® in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
Freitag 1 März 2024 (3 Monate vor) • GlobeNewswire Inc.

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Donnerstag 29 Februar 2024 (3 Monate vor) • Edgar (US Regulatory)

Form 8-K - Current report
Mittwoch 28 Februar 2024 (3 Monate vor) • Edgar (US Regulatory)

TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2023 Financial Results
Mittwoch 28 Februar 2024 (3 Monate vor) • GlobeNewswire Inc.

TG Therapeutics Announces Issuance of Additional Patents for BRIUMVI® (ublituximab-xiiy)
Dienstag 27 Februar 2024 (3 Monate vor) • GlobeNewswire Inc.

Weitere TG Therapeutics Inc News-Artikel

Novatek Joint Stock (CE)

Vontobel Financial Produ...

Athabasca Minerals (PK)

NLBNPIT21PV3 20240920 34...

Net Zero Renewable Energy

Entergy Louisiana LLC

Societe Generale Effekten

Vontobel Financial Produ...

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen